Shares of Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) reached a new 52-week low during mid-day trading on Friday . The company traded as low as $80.08 and last traded at $81.68, with a volume of 1492586 shares trading hands. The stock had previously closed at $87.11.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on BPMC shares. Guggenheim reaffirmed a "buy" rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. Morgan Stanley initiated coverage on shares of Blueprint Medicines in a research note on Thursday, March 20th. They set an "equal weight" rating and a $100.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. Wolfe Research assumed coverage on Blueprint Medicines in a research report on Tuesday, March 18th. They set an "outperform" rating for the company. Finally, Jefferies Financial Group initiated coverage on Blueprint Medicines in a research note on Monday, March 17th. They set a "buy" rating and a $135.00 target price on the stock. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $124.95.
Check Out Our Latest Report on Blueprint Medicines
Blueprint Medicines Stock Performance
The company's 50-day simple moving average is $92.19 and its 200-day simple moving average is $93.62. The stock has a market capitalization of $4.98 billion, a price-to-earnings ratio of -72.43 and a beta of 0.75. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.
Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, analysts expect that Blueprint Medicines Co. will post -1.28 EPS for the current year.
Insider Buying and Selling at Blueprint Medicines
In related news, CEO Kate Haviland sold 1,446 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the transaction, the chief executive officer now owns 149,378 shares of the company's stock, valued at approximately $16,467,430.72. The trade was a 0.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Christina Rossi sold 2,274 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.14, for a total value of $250,458.36. Following the transaction, the chief operating officer now directly owns 67,109 shares of the company's stock, valued at $7,391,385.26. The trade was a 3.28 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,608 shares of company stock valued at $3,319,587. Company insiders own 4.21% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of BPMC. Empirical Asset Management LLC purchased a new position in Blueprint Medicines during the 4th quarter valued at about $2,348,000. Stephens Inc. AR purchased a new stake in Blueprint Medicines during the 4th quarter valued at $321,000. Bank of New York Mellon Corp lifted its holdings in Blueprint Medicines by 2.4% in the fourth quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company's stock valued at $26,465,000 after acquiring an additional 7,101 shares during the period. KBC Group NV grew its position in Blueprint Medicines by 63.9% during the fourth quarter. KBC Group NV now owns 2,625 shares of the biotechnology company's stock valued at $229,000 after buying an additional 1,023 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Blueprint Medicines in the 4th quarter worth $21,104,000.
About Blueprint Medicines
(
Get Free Report)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Featured Articles
Before you consider Blueprint Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Blueprint Medicines wasn't on the list.
While Blueprint Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
